Suppr超能文献

主动联合腹膜透析和血液透析治疗对技术生存率和死亡率的影响。

Effect of proactive combination therapy with peritoneal dialysis and hemodialysis on technique survival and mortality.

机构信息

Department of Nephrology, Hitachi General Hospital, 2-1-1 Johnan-Cho, Hitachi, Ibaraki, 317-0077, Japan.

Department of Nephrology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.

出版信息

J Artif Organs. 2024 Dec;27(4):429-434. doi: 10.1007/s10047-024-01437-z. Epub 2024 Mar 22.

Abstract

PURPOSE

Clinically relevant evidence for the timing of starting combination therapy with peritoneal dialysis and hemodialysis remains scarce. We retrospectively examined whether combination therapy during the induction phase of dialysis prolongs peritoneal dialysis duration.

METHODS

This retrospective study includes 160 patients who underwent combination therapy from 20 dialysis facilities. Four groups were categorized: combination at peritoneal dialysis induction (n = 12, Proactive combination group), and combination following peritoneal dialysis durations of < 2 years (n = 65), 2-5 years (n = 70), or > 5 years (n = 13). Differences in technique survival of dialysis, mortality, and hospitalization due to cardiovascular events in the groups were observed.

RESULTS

The Proactive combination group had the longer mean duration of combination therapy (3.18 years) comparing to that of combination therapy following peritoneal dialysis (1.45 years), but total peritoneal dialysis duration was shorter than in control groups (4.02 years). Of the 160 cases in the entire cohort, there were 8 deaths, 18 ischemic heart disease hospitalizations, and 18 stroke hospitalizations. The Proactive group had lower crude mortality rate (0/12 cases, 0.0%) and crude hospitalization rate for ischemic heart disease (1/11, 8.3%) than the other groups. However, this cohort study did not have enough statistical power to adjust for patients' background, and we were unable to fully examine the differences in such clinical outcomes by the timing of initiation of combination therapy.

CONCLUSION

Use of combination therapy in the induction phase might prolong the duration of combination therapy, but is not necessarily effective for prolonging peritoneal dialysis technique survival.

摘要

目的

腹膜透析和血液透析联合治疗开始时机的临床相关证据仍然缺乏。我们回顾性研究了透析诱导期开始联合治疗是否会延长腹膜透析时间。

方法

本回顾性研究纳入了 160 名在 20 家透析中心接受联合治疗的患者。将患者分为 4 组:腹膜透析诱导期开始联合治疗(n=12,主动联合组)、腹膜透析时间<2 年(n=65)、2-5 年(n=70)和>5 年(n=13)时开始联合治疗。观察各组透析技术生存率、死亡率以及心血管事件导致的住院率差异。

结果

主动联合组的联合治疗平均持续时间(3.18 年)明显长于腹膜透析后开始联合治疗(1.45 年),但总腹膜透析时间短于对照组(4.02 年)。在整个队列的 160 例患者中,有 8 例死亡,18 例缺血性心脏病住院,18 例中风住院。主动组的粗死亡率(0/12 例,0.0%)和缺血性心脏病粗住院率(1/11,8.3%)低于其他组。然而,本队列研究的统计效力不足以调整患者背景,我们无法充分检查不同联合治疗开始时机对这些临床结局的差异。

结论

在诱导期使用联合治疗可能会延长联合治疗的持续时间,但不一定能有效延长腹膜透析技术的生存时间。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验